CN1895346A - Chinese-medicinal preparation for treating cardivascular and cerebrovascular diseases and its making method - Google Patents
Chinese-medicinal preparation for treating cardivascular and cerebrovascular diseases and its making method Download PDFInfo
- Publication number
- CN1895346A CN1895346A CN 200610051007 CN200610051007A CN1895346A CN 1895346 A CN1895346 A CN 1895346A CN 200610051007 CN200610051007 CN 200610051007 CN 200610051007 A CN200610051007 A CN 200610051007A CN 1895346 A CN1895346 A CN 1895346A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- preparation
- medicine preparation
- chinese
- salviae miltiorrhizae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine 'Tongmai oral liquid' for treating cardiovascular and cerebrovascular diseases is prepared from red sage root, Chuan-xiong rhizome and pueraria root. Its preparing process is also disclosed.
Description
Technical field:
The present invention relates to a kind of Chinese medicine preparation and preparation method for the treatment of cardiovascular and cerebrovascular disease, particularly relate to TONGMAI KOUFUYE and other pharmaceutical preparation made from Chinese medicines such as Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Radix Puerariaes.
Technical background:
Ischemic cardio cerebrovascular diseases mainly comprises coronary atherosclerotic heart disease (coronary heart disease), cerebral infarction, all kinds of angina pectoris and transient ischemic attack, and arteriosclerosis, cerebral thrombosis, angina pectoriss etc. are again cardiovascular system commonly encountered diseases, frequently-occurring disease.Because China begins to enter aging society, rhythm of life is constantly accelerated, and the change of dietary structure etc., cardiovascular medicament is sold speedup and is higher than world's growth level.The health ministry statistical data shows that the ratio of 2000-2020 China over-65s aging population will rise to 26.15% from 7.09%, calculate and will surpass 3.9 hundred million with 1,500,000,000 total populations, and old people's cardiovascular and cerebrovascular vessel sickness rate be up to 60%-70%.And cardiovascular and cerebrovascular disease also becomes some young and middle-aged people's in the prime of life " potential killer " statistical data and shows that the domestic cardiovascular and cerebrovascular vessel Chinese patent medicine of 1999-2003 market average speed of growth is 23.75%.Come after the anti-infection drug with second largest class medicine.Although the Chinese Traditional Cardiovascular Medicine market scale is big, but still be the leading market of big kind, as FUFANG DANSHEN DIWAN, Tongxinluo, BUCHANG NAOXINTONG, DIAOXINXUE KANG, SUXIAO JIUXIN WAN, SHUXUENING and MAILUONING etc., because these Chinese patent medicines are in the market sale scale, brand is big, dosage form is good, but costs an arm and a leg, and causes most of cardiovascular patients that this is hung back.In addition, some medicine is cured the symptoms, not the disease, and some uncertain therapeutic efficacies in application process are cut and interrupted using in addition.And existing TONGMAI KOUFUYE extraction process is coarse, the extraction process of the TONGMAI KOUFUYE that is numbered WS3-B-3980-98 that for example ministry standard is published just has following deficiency: this technology Chinese crude drug directly decocts without just soaking, and the too low effective ingredient that more makes of extractum relative density does not propose fully in addition; Secondly, because diabetes and cardiovascular disease have confidential relation, and the oral liquid that former method is made contains sucrose, is unsuitable for those cardiovascular diseasess and has the sick patient's use of diabetes complicated card concurrently.
For this reason, the present invention overcomes original deficiency on this basis, provide that a kind of better quality, curative effect increase, cheap oral liquid formulations, both developed the traditional characteristics of oral liquid, take for those cardiovascular patients again and brought convenience, increased compliance with critical patient, old man, factor such as esophagus is narrower and small, gastrointestinal function is more weak.
Summary of the invention:
Purpose of the present invention is to provide a kind of Chinese medicine preparation for the treatment of cardiovascular and cerebrovascular disease, and said preparation is made by following Chinese medicinal raw materials.
Radix Salviae Miltiorrhizae 101～999g Rhizoma Chuanxiong 101～999g Radix Puerariae 101～999g
Preferably:
Radix Salviae Miltiorrhizae 301～699g Rhizoma Chuanxiong 301～699g Radix Puerariae 301～699g
More preferably:
Radix Salviae Miltiorrhizae 500g Rhizoma Chuanxiong 500g Radix Puerariae 500g
In more than forming, weight is calculated with crude drug, and this prescription composition can be made into 1000 doses in preparation, described 1000 doses are meant, the final drug preparation of making, as make oral liquid 1000ml, as oral liquid, can be with packing greatly, as the bottle of 10-500ml, if be the bottle of 10ml, more than prescription can be made 100 bottles of oral liquids, if the bottle packing of 500ml, more than prescription can be made 2 bottles of oral liquids.
In more than forming, can be made into 50-1000 taking dose of preparation,, make 100 bottles in the bottle of 10ml, take the 1-2 bottle at every turn, can take 50-100 time altogether as oral liquid.
More than form to be by weight as proportioning, when producing, can or reduce according to the corresponding proportion increase, as large-scale production can be unit with the kilogram, or be unit with the ton, small-scale production can be a unit with gram or milligram also, weight can increase or reduce, but the constant rate of the raw medicinal herbs weight proportion between each composition.
The ratio of above weight proportion obtains through science screening, for especial patient, and as serious symptom or light disease, fat or modest patient, the proportioning of the amount of can corresponding adjustment forming increases or reduces being no more than 100%, and drug effect is constant.
Raw material of Chinese medicine in more than forming can be replaced with the suitable Chinese medicine with identical property of medicine, and its drug effect of the Chinese medicine preparation after the replacement is constant.
Chinese medicine preparation of the present invention is to process through extraction or other modes by the Chinese medicine crude drug that above-mentioned prescription is formed, and makes pharmaceutically active substance, subsequently, with this material is raw material, adds the medicine acceptable carrier when needing, and makes according to the routine techniques of galenic pharmacy.Described active substance can obtain by extracting the former medicine of Chinese medicine respectively, also can obtain by the former medicine of co-extracted Chinese medicine, can also obtain by other modes, as by pulverize, squeeze, calcine, grind, sieve, percolation, extraction, water are carried, alcohol extraction, ester are carried, methods such as ketone is carried, chromatography obtain, these active substances can be the material of extractum form, can be that dry extract also can be a fluid extract, make different concentration according to the different needs decision of preparation.
Pharmaceutically active substance in the Chinese medicine preparation of the present invention, its shared percentage by weight in preparation can be 0.1-99.9%, and all the other are the medicine acceptable carrier, and as oral liquid, preferred carrier is: water, cyclamate and Pyrusussuriensis formic acid.Chinese medicine preparation of the present invention exists with unit dosage form, and described unit dosage form is meant the unit of preparation, as every of tablet, and capsular every, every bottle of oral liquid etc., in the unit dose, the amount that contains active substance is 5-800mg, preferably 20-500mg.
Pharmaceutical preparation of the present invention can also be any pharmaceutically useful dosage form, and these dosage forms comprise capsule, tablet, oral liquid, syrup, granule, pill, powder, unguentum, sublimed preparation, spray, injection, drop pill, slow controlling agent.
Pharmaceutical preparation of the present invention, the preparation of its oral administration can contain additives commonly used, such as sweeting agent, binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, correctives and wetting agent, can carry out coating to tablet in case of necessity.
The form of oral liquid for example can be aqueous or oily suspensions, solution, Emulsion, syrup, perhaps can be the suitable carrier of a kind of available water before use or other composite dry products.This liquid preparation can contain conventional additives, as suspending agent, for example fat is used in sorbitol, syrup, methylcellulose, gelatin, carboxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenation, for example lecithin or arabic gum, for example almond oil, propylene glycol, antiseptic, for example hydroxy benzenes methyl ester or to benzene hydroxyl propyl formate or sorbic acid, if desired, can contain conventional flavouring agent and coloring agent.
Pharmaceutical preparation of the present invention, when making preparation, can select to add the medicine acceptable carrier as required, these carriers can be any carriers that is fit to make pharmaceutical preparation, as: mannitol, sorbitol, sorbic acid or potassium salt, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin A, vitamin C, vitamin E, vitamin D, azone, the EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, propylene glycol, ethanol, soil temperature 60-80, Arlacel-80, Cera Flava, lanoline, liquid paraffin, hexadecanol, gallate ester, agar, triethanolamine, basic amino acid, carbamide, allantoin, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
The present invention presses following prepared:
Radix Salviae Miltiorrhizae 500g Rhizoma Chuanxiong 500g Radix Puerariae 500g cyclamate 5g potassium sorbate 2.5g
Method for making: above three flavors, add 8 times of water logging bubbles 6 hours, decoct 2 times, 1.5 hours for the first time, 1 hour collecting decoction filtered for the second time, relative density was 1.08 when filtrate was concentrated into 60 ℃, filtered while hot, and relative density is 1.39 clear paste during filtrate cryoconcentration to 60 ℃.Add cyclamate, potassium sorbate, distilled water are adjusted total amount to 1000ml, stir evenly, and cold preservation was left standstill 12 hours, filtered, and fill is sealed in 100 bottles of 10ml bottles totally under aseptic or half aseptic condition, and sterilization promptly gets oral liquid.
Consider that Chinese medicine oral liquid is a kind of dosage form of developing on the decoction basis, have easy absorption, little, the taking convenience of dosage, and be applicable to characteristics such as the big production of industry, by drug effect, clinical trial, its oral liquid formulation good effect.Therefore preferably decide oral liquid as this pharmaceutically dosage form.Oral liquid formulations of the present invention is made by Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Radix Puerariae etc., first at the cardiovascular disease, and treating both the principal and secondary aspects of a disease, medicine letter power is special; Second prescription is simplified, and is scientific and reasonable.
Below pass through the beneficial effect of pharmacodynamics test data declaration oral liquid of the present invention:
Oral liquid of the present invention (in this called after TONGMAI KOUFUYE) with the preparation of the method for embodiment 1 experimentizes.
Below for to cure mainly relevant Pharmacodynamic test of active extract with function:
Test example one: arteriosclerosis (AS) experiment
One, material:
1, medicine: TONGMAI KOUFUYE, according to method of the present invention preparation, the test lot number: 20040507, specification 10ml * 10, content: 1.5g crude drug/ml.
2, animal: 24 Kunming kind White Rabbits provide by Guiyang Medical College.
Two, experimental technique and result
1, the atherosis model of rabbit arterial set up 24 Kunming kind White Rabbits, forage feed 7d routinely is divided into 8 of high fat groups, 8 of the groups of promoting blood circulation and 8 of normal control groups at random.Matched group is raised with the conventional granulates feedstuff; High fat group is raised with high cholesterol diet (1% cholesterol adds the pellet of 5% Adeps Sus domestica); The TONGMAI KOUFUYE group is raised with high cholesterol diet and is added TONGMAI KOUFUYE 0.5g/ (kgd), feeds altogether 4 months.
2, histopathologic examination's animal feeding through the auricular vein anesthetized animal, was got thoracic aorta with 2% pentobarbital sodium 2mL/kg after 4 months, it is fixing to put into 4% paraformaldehyde immediately, conventional up gradient alcohol dehydration, the routine paraffin wax embedding, stand-by Vascular Slice is made with the HE colouring method.Lipid determination adopts Enzymology method, and unit represents that with mmol/L reverse transcriptional PCR (RT-PCR) detects the equal mRNA of blood vessel MCP-1 and expresses.
3, the statistical procedures experimental data is with mean ± standard deviation (X ± s) expression.Use SAS software and analyze, mean is relatively used variance analysis between many groups; Mean is relatively checked with t between two groups.
Three results
The endarterium of the high fat group of the morphologic variation of 1 vascular pathological obviously thickens, rough and uneven in surface, observation can be seen a large amount of foam cells under the light microscopic, the remaining endotheliocyte of minority distributes irregular, and interior elastic plate fracture has clearly illustrated typical atherosclerotic pathological changes.And TONGMAI KOUFUYE group endarterium also has irregular thickening, and is rough and uneven in surface, but the higher fat group of AS degree alleviates, and light microscopic is found intimal thickening down, has the foam cell that is dispersed in to exist.The morphology of conventional group vascular pathological shows that inner membrance, middle film and adventitia are complete, and endotheliocyte is complete.
2, aorta MCP-1mRNA expresses the RT-PCR demonstration, the matched group aorta does not have the expression of MCP-1mRNA, high fat group Reinhoit Zahl (1.00 ± 0.09), and the group oral liquid group Reinhoit Zahl (0.64 ± 0.03) of promoting blood circulation, higher fat group is obviously reduced (n=4, P＜0.05).
3, after this experimentation of conclusion was set up the AS rabbit model, the endarterium of observing high fat group from pathomorphism obviously thickened, rough and uneven in surface, observation can be seen a large amount of foam cells under the light microscopic; And TONGMAI KOUFUYE group endarterium also has irregular thickening, and is rough and uneven in surface, but the higher fat group of AS degree alleviates, and light microscopic is found intimal thickening down, has the foam cell that is dispersed in to exist, and illustrates that TONGMAI KOUFUYE has anti-AS effect.Discover that simultaneously TONGMAI KOUFUYE treatment of the present invention can significantly reduce aortic blood tube wall MCP-1 expression of gene, prompting the present invention has the AS inflammatory effect.
Test example two: the anti-cerebral thrombosis effect research of oral liquid of the present invention
One, materials and methods
1.1 animal SD rat, body weight 250～300g, male, section provides by the Guiyang Medical College laboratory animal, an animal licence numbering GYS (expensive) 200420003.The SHR rat, spontaneous hypertensive rat (SHR), the male and female dual-purpose, 8 ages in week, body weight 200～240g, section provides by the Guiyang Medical College laboratory animal.
1.2 medicine and instrument TONGMAI KOUFUYE, Guizhou Yibai Pharmaceutical Co., Ltd provides, the test lot number: 20040507, and specification 10ml/ props up, content: 1.5g crude drug/ml.Urokinase: the Tianjin Biochemical Pharmaceutical Factory produces, lot number 20030520.Nimodipine, Livzon Pharmaceutical Factory, Livzon Group production, lot number 041022; CGRP (lot number: 200425334) put and exempt from medicine box and put available from PLA General Hospital Science and Technology Development Center and exempt from institute.GC2911 γ radioimmunity enumerator, University of Science and Technology of China,technology industry Corp's product.1.3 focal embolic rats with cerebral ischemia Preparation of model, get body weight 250～300gSD rat or SHR rat, pentobarbital sodium (35mgPkg, ip) anesthesia, routine disinfection, at right eye outer canthus and right external ear: the mid point of road line is made a curved incision, separates temporalis, is separated to ala magna ossis sphenoidalis downwards along zygomatic arch, open the bone window of one 4 * 4mm with dental burr, find the medium-sized artery branch herein, the directly about 0.5mm of cut-off, be about the 5cm cotton thread, with 50%FeCl
3Moistening one end (about 0.5mm) puts in about 0.5mm to the front lower place along the medium-sized artery branch, is affixed on its preceding hypomere, and the moistening cotton balls covers, and takes out cotton thread behind the placement 20min, and sewing up the incision gets final product.Sham operated rats substitutes 50%FeCl by last method with injecting normal saline
3The moistening cotton thread.
1.4 grouping and administration
To the early stage influence of ischemia: after SD rat modeling operation finishes, be divided into 7 groups by the body weight stratified random, it is sham operated rats, model group, TONGMAI KOUFUYE heavy dose (10ml * 20 Pkg) group, middle dosage (10ml * 10 Pkg) group, low dose of (10ml * 5 Pkg) group, nimodipine (10mgPkg) group, urokinase group (300,000 UPkg) group, administration immediately 1 time, except that urokinase group ip, all the other each groups are gastric infusion, sham operated rats and model group are given the distilled water with volume, each repeat administration of 5h and 23h is 1 time after surgery, postoperative 6h and 24h take a blood sample through eye socket, separated plasma, standby; And, get brain fast 24h blood sampling back execution animal, and the dry ice quick-freezing ,-80 ℃ of preservations are standby.
Influence to the ischemia later stage: other gets the SD rat, and modeling as stated above is after operation finishes, grouping situation same acute stage,, administration immediately 1 time removes urokinase group China and foreign countries, all the other each groups are gastric infusion, and sham operated rats and model group are given the distilled water with volume, and repeat administration is 1 time behind the 6h, at 7 day next day to the, administration every day was 1 time, animal is put to death in the 1h blood sampling after the last administration, gets brain fast, the dry ice quick-freezing ,-80 ℃ of preservations are standby.
Influence to SHR: get the SHR rat, duplicate focal embolic rats with cerebral ischemia model as stated above, after operation finishes, be divided into 5 groups at random, be sham operated rats, model group, TONGMAI KOUFUYE heavy dose (10ml * 20 Pkg) group, middle dosage (10ml * 10 Pkg) group, low dose of (10ml * 5 Pkg) group, nimodipine (10mgPkg) group, postoperative administration immediately 1 time, each repeat administration of 6h and 23h is 1 time after surgery, 1h puts to death animal after the last administration, get brain fast, the dry ice quick-freezing ,-80 ℃ of preservations are standby.
1.5 tissue is drawn materials and the about 3mL of rat eye socket blood is got in processing, puts into the centrifuge tube that is added with 10%EDTA22Na30 μ L and aprotinin 1500U, (4 ℃, 3500rpm), separated plasma is measured CGRP content respectively by the test kit explanation to centrifugal 10min.Get rat whole brain, normal saline boils 10min, with the central point between tuber cinereum and the optic chiasma is that hypothalamus is determined at the center, take by weighing a certain amount of inferior colliculus cerebral tissue respectively, add 1N glacial acetic acid 700 μ L, homogenate, add 1NNaOH700 μ L neutralization, centrifugal 30min (4 ℃ 3000rpm), are got supernatant and measure CGRP content respectively.CGRP content is represented with pgPmL in the blood plasma, represents with the pgPmg tissue wet in the tissue.1.6 statistical method respectively organize experimental data all with mean ± standard deviation (expression of X ± s), group difference relatively use the sided t method of inspection.
2 results
2.1 TONGMAI KOUFUYE is to the influence of CGRP content by table 1 result as seen, behind the focal embolic cerebral ischemia of the rat 6h, and the remarkable rising that plasma C GRP content one is crossed property, 24h is lower than sham operated rats, and 7d rises to normal level again after modeling.The dosage group is influential to the rising that CGRP in the cerebral ischemia 6h blood plasma one crosses property in the TONGMAI KOUFUYE, and large, medium and small three dosage groups all have the antagonism of significance to the reduction of ischemia 24hCGRP, and ischemia is not seen obvious influence late period.24h and 7d after the focal embolic cerebral ischemia of rat due to this experimental technique, CGRP content does not all have obvious change in the inferior colliculus cerebral tissue, and TONGMAI KOUFUYE is not also seen obvious influence (table 2) to this.
Table 1 TONGMAI KOUFUYE is to the influence of focal embolic rats with cerebral ischemia plasma C GRP content
| Group | Dosage (mgPkg) | CGRP(pgPmL) | ||
| 6h | 24h | 7d | ||
| Sham operated rats model group urokinase nimodipine TONGMAI KOUFUYE | --30 ten thousand U 10 100 200 400 | 217.47±184.62(6) 634.38±448.19(8) 1) 272.94±165.53(10) 469.24±244.29(6) 270.95±149.12(6) 226.48±105.15(8) 2) 443.78±189.8(9) | 221.21±129.19(7) 102.04±54.99(9)1) 454.55±326.542(7) 2) 268.86±155.1967(7) 2) 176.68±39.95(5) 2) 288.79±191.11(9) 2) 329.73±237.57(8) 2) | 178.68±34.00(11) 175.17±74.65(11) 206.37±132.68(12) 164.78±55.26(12) 206.89±77.08(11) 173.61±40.13(12) 184.46±65.60(12) |
Annotate: compare 1 with sham operated rats) P＜0.05; Compare 2 with model group) P＜0.05; In () bracket is the example number.Down together.
Table 2 TONGMAI KOUFUYE is to the influence of focal embolic rats with cerebral ischemia hypothalamus CGRP content
| Group | Dosage (mgPkg) | CGRP (the pgPmg cutaneous horn is heavy) | |
| 24h after the modeling | 7d after the modeling | ||
| Sham operated rats model group urokinase nimodipine TONGMAI KOUFUYE | --30 ten thousand U 10 100 200 400 | 11.91±3.80(7) 15.93±3.79(8) 11.54±4.99(10) 12.92±4.87(7) 11.83±5.29(9) 12.38±4.80(9) 10.40±5.33(7) | 14.79±2.20(11) 15.71±1.39(12) 14.04±3.06(11) 14.56±2.05(11) 15.47±4.60(8) 15.70±5.55(12) 15.12±4.21(12) |
3 these experimental results of conclusion show, phase change when back Plasma level of CGRP generation takes place the SD rat cerebral ischemia.Early stage at ischemia, CGRP is the property a crossed rising, and 24h behind the ischemia, CGRP are starkly lower than sham operated rats again, 7d after the modeling, and CGRP returns to normal level.This experimentation finds that also TONGMAI KOUFUYE has remarkable rising effect to the CGRP value that modeling animal hypothalamus reduces under the similarity condition.
The result; TONGMAI KOUFUYE mainly has the improvement effect to the ANOMALOUS VARIATIONS of the early stage CGRP of ischemia, and based on CGRP content in rising blood plasma and the hypothalamus, thereby make it to keep stable; improve the cerebrovascular state that contracts that relaxes, and performance CGRP is to the protective effect of neurocyte ischemic injuries.
The present invention is directed to prior art, because seeking medical advice to intracardiac section, the diabetic of cardiovascular disease complication resembles the coronary heart disease patient who merges by diabetes for those especially, can not take the product that contains a large amount of sugar parts, we are necessary to address these problems from adjuvant for this reason, to make things convenient for those coronary heart disease high-risk group medication demand, reach the purpose of treatment.
The specific embodiment:
Further specify the present invention by the following examples.
Embodiment 1:
Prescription: Radix Salviae Miltiorrhizae 500g Rhizoma Chuanxiong 500g Radix Puerariae 500g cyclamate 5g potassium sorbate 2.5g
Method for making: above three flavors, add 8 times of water logging bubbles 6 hours, decoct 2 times, 1.5 hours for the first time, 1 hour collecting decoction filtered for the second time, relative density was 1.08 when filtrate was concentrated into 60 ℃, filtered while hot, and relative density is 1.39 clear paste during filtrate cryoconcentration to 60 ℃.Add cyclamate, potassium sorbate, distilled water are adjusted total amount to 1000ml, stir evenly, and cold preservation was left standstill 12 hours, filtered, and fill is sealed in 100 bottles of 10ml bottles totally under aseptic or half aseptic condition, and sterilization promptly gets oral liquid.
Embodiment 2:
Prescription: Radix Salviae Miltiorrhizae 101g Rhizoma Chuanxiong 101g Radix Puerariae 101g cyclamate 5g potassium sorbate 2.5g
Method for making: above three flavors, add 8 times of water logging bubbles 6 hours, decoct 2 times, 1.5 hours for the first time, 1 hour collecting decoction filtered for the second time, relative density was 1.08 when filtrate was concentrated into 60 ℃, filtered while hot, and relative density is 1.39 clear paste during filtrate cryoconcentration to 60 ℃.Add cyclamate, potassium sorbate, distilled water are adjusted total amount to 1000ml, stir evenly, and cold preservation was left standstill 12 hours, filtered, and fill is sealed in 100 bottles of 10ml bottles totally under aseptic or half aseptic condition, and sterilization promptly gets oral liquid.
Embodiment 3:
Prescription: Radix Salviae Miltiorrhizae 999g Rhizoma Chuanxiong 999g Radix Puerariae 999g cyclamate 5g potassium sorbate 2.5g
Method for making: above three flavors, add 8 times of water logging bubbles 6 hours, decoct 2 times, 1.5 hours for the first time, 1 hour collecting decoction filtered for the second time, relative density was 1.08 when filtrate was concentrated into 60 ℃, filtered while hot, and relative density is 1.39 clear paste during filtrate cryoconcentration to 60 ℃.Add cyclamate, potassium sorbate, distilled water are adjusted total amount to 1000ml, stir evenly, and cold preservation was left standstill 12 hours, filtered, and fill is sealed in 100 bottles of 10ml bottles totally under aseptic or half aseptic condition, and oral liquid is made in sterilization, promptly.
Embodiment 4:
Prescription: Radix Salviae Miltiorrhizae 301g Rhizoma Chuanxiong 301g Radix Puerariae 301g cyclamate 5g potassium sorbate 2.5g
Method for making: above three flavors, add 8 times of water logging bubbles 6 hours, decoct 2 times, 1.5 hours for the first time, 1 hour collecting decoction filtered for the second time, relative density was 1.08 when filtrate was concentrated into 60 ℃, filtered while hot, and relative density is 1.39 clear paste during filtrate cryoconcentration to 60 ℃.Add cyclamate, potassium sorbate, distilled water are adjusted total amount to 1000ml, stir evenly, and cold preservation was left standstill 12 hours, filtered, and fill is sealed in 100 bottles of 10ml bottles totally under aseptic or half aseptic condition, and oral liquid is made in sterilization, promptly.
Embodiment 5:
Prescription: Radix Salviae Miltiorrhizae 699g Rhizoma Chuanxiong 699g Radix Puerariae 699g cyclamate 5g potassium sorbate 2.5g
Method for making: above three flavors, add 8 times of water logging bubbles 6 hours, decoct 2 times, 1.5 hours for the first time, 1 hour collecting decoction filtered for the second time, relative density was 1.08 when filtrate was concentrated into 60 ℃, filtered while hot, and relative density is 1.39 clear paste during filtrate cryoconcentration to 60 ℃.Add cyclamate, potassium sorbate, distilled water are adjusted total amount to 1000ml, stir evenly, and cold preservation was left standstill 12 hours, filtered, and fill is sealed in 100 bottles of 10ml bottles totally under aseptic or half aseptic condition, and oral liquid is made in sterilization, promptly.
Claims (10)
1, a kind of Chinese medicine preparation for the treatment of cardiovascular and cerebrovascular disease is characterized in that, per 1000 dosage units are made by following Chinese medicinal raw materials,
Radix Salviae Miltiorrhizae 101～999g Rhizoma Chuanxiong 101～999g Radix Puerariae 101～999g.
2, the Chinese medicine preparation of claim 1 is characterized in that, per 1000 dosage units are made by following Chinese medicinal raw materials,
Radix Salviae Miltiorrhizae 301～699g Rhizoma Chuanxiong 301～699g Radix Puerariae 301～699g.
3, the Chinese medicine preparation of claim 1 is characterized in that, per 1000 dosage units are made by following Chinese medicinal raw materials,
Radix Salviae Miltiorrhizae 500g Rhizoma Chuanxiong 500g Radix Puerariae 500g.
4, the Chinese medicine preparation of claim 1-3 is the suitable various dosage forms that will use.
5, the Chinese medicine preparation of claim 4 is oral liquids.
6, the Chinese medicine preparation of claim 5 wherein also comprises medicine acceptable carrier.
7, the Chinese medicine preparation of claim 1 preparation prevention/or the medicine of treatment cardiovascular and cerebrovascular disease in application.
8, the preparation method of the Chinese medicine preparation of claim 1 is characterized in that, through step once,
Get equivalent Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong and Radix Puerariae, add 8 times of water logging bubbles 6 hours, decoct 2 times, 1.5 hours for the first time, 1 hour collecting decoction filtered for the second time, relative density was 1.08 when filtrate was concentrated into 60 ℃, filter while hot, relative density is 1.39 clear paste during filtrate cryoconcentration to 60 ℃, obtains pharmaceutically active substance.
9, the preparation method of Chinese medicine preparation according to Claim 8 is characterized in that,
The active substance that the method for claim 8 obtains is pressed pharmaceutical dosage form and is added adjuvant, makes preparation with the galenic pharmacy routine techniques.
10, the described carrier according to claim 6 is preferably: water, cyclamate and Pyrusussuriensis formic acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610051007 CN1895346A (en) | 2006-04-18 | 2006-04-18 | Chinese-medicinal preparation for treating cardivascular and cerebrovascular diseases and its making method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610051007 CN1895346A (en) | 2006-04-18 | 2006-04-18 | Chinese-medicinal preparation for treating cardivascular and cerebrovascular diseases and its making method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1895346A true CN1895346A (en) | 2007-01-17 |
Family
ID=37608084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610051007 Pending CN1895346A (en) | 2006-04-18 | 2006-04-18 | Chinese-medicinal preparation for treating cardivascular and cerebrovascular diseases and its making method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1895346A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110507765A (en) * | 2019-09-10 | 2019-11-29 | 罗琢滨 | A kind of compound Maitong piece preparation method |
| CN115919929A (en) * | 2022-12-01 | 2023-04-07 | 金华寿仙谷药业有限公司 | Antioxidant traditional Chinese medicine composition and application thereof |
-
2006
- 2006-04-18 CN CN 200610051007 patent/CN1895346A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110507765A (en) * | 2019-09-10 | 2019-11-29 | 罗琢滨 | A kind of compound Maitong piece preparation method |
| CN115919929A (en) * | 2022-12-01 | 2023-04-07 | 金华寿仙谷药业有限公司 | Antioxidant traditional Chinese medicine composition and application thereof |
| CN115919929B (en) * | 2022-12-01 | 2024-07-09 | 金华寿仙谷药业有限公司 | Antioxidant traditional Chinese medicine composition and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103006838B (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN1757400A (en) | Traditional Chinese medicine granule, and its prepn. method | |
| CN103006769B (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1679706A (en) | Medicinal preparation containing notoginseng and rhodiola root for cardio-cerebral blood vessel diseases and its preparing method | |
| CN1733081A (en) | Chinese medicine preparation for nourishing blood and tranquilizing mind and its preparation process | |
| CN1895346A (en) | Chinese-medicinal preparation for treating cardivascular and cerebrovascular diseases and its making method | |
| CN1853689A (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and making method thereof | |
| CN1853688A (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof | |
| CN1248698C (en) | Drug for treating coronary heart disease or coronary disease and cardiac insufficiency, and its preparation method | |
| CN1081465C (en) | Rhodiola rosea injection for treating angina pectoris of coronary heart disease | |
| CN1294948C (en) | Medicine for boosting qi, strengthening spleen and nourishing liver and kidney and its preparation method | |
| CN1220510C (en) | Chinese patent medicine with the functions of replenishing qi and blood and nourishing the heart to calm the mind, its preparation method and quality control method | |
| CN1899410A (en) | Medicine for treating cardiovascular disease and its preparing method and quality control method | |
| CN1689637A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1899373A (en) | Medicinal composition for treating coronary heart disease | |
| CN1939383A (en) | Use of redback christmashush in preparing medicine for hepatitis B | |
| CN1679700A (en) | Medicinal preparation containing notoginseng and pueraria root for treating cardio-cerebral blood vessel diseases and its preparing method | |
| CN103263581A (en) | Shuangshen capsule for reducing blood sugar | |
| CN1557403A (en) | Medicine for treating angiocardiopathy and cerebrovascular disease and its preparing method | |
| CN108567753A (en) | All beam dripping pill and its preparation process | |
| CN100482264C (en) | Shenling Chinese medicine preparation for strengthening body resistance | |
| CN1286480C (en) | Oral disintegrants of composite salvia miltiorrhiza and their preparation | |
| CN1954857A (en) | Traditional Chinese medicinal compound preparation for treating asthma and its preparation method | |
| CN1559469A (en) | Prepn. method for freezing-drying powder injection for treating cardiovascular disease | |
| CN105687499A (en) | Betaxolol containing pharmaceutical composition for treating hypertension and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |